BioInvent to Expand Pipeline With New Development Programs in Solid Cancer

LUND, Sweden, Oct. 16, 2018  /PRNewswire/ -- BioInvent International AB (OMXS: BINV) today announced its intention to initiate three new clinical programs in solid cancer. In addition to the previously disclosed programs (BI-1206 + rituximab – projected topline results H1 2020; and the Transgene and Pfizer collaborations), and subject to successful preclinical results and sufficient financial resources, BioInvent intends to advance the following programs in solid cancer: anti FcγRllB antibody/anti-PD1 antibody – projected start phase l/lla in H1 2019; BI-1607, an anti FcγRllB antibody/check point inhibitor – projected start phase l proof of concept trial in H2 2019; BI-1808 (anti-"EmergingTNFRS" antibody) +/- anti-PD1 antibody – projected start phase l in H1 2020.

On December 10, BioInvent has the pleasure to invite investors, financial analysts and media to attend the Company's Capital Markets Day at the IVA Conference Center, Grev Turegatan 16 in Stockholm between 2 pm and 4 pm. BioInvent has made a concerted effort over the past months to reframe its equity story to better bring out its value drivers – the strength of its discovery platform, the scientific and clinical rationale of targeting Fc gamma receptors in cancer immunotherapy and its leadership in that space, the substantial unmet medical need of the cancer indications it is pursuing, and the associated commercial opportunity.

Speakers at the Capital Markets Day include Martin Welschof, CEO, Björn Frendéus, Chief Scientific Officer and Andres McAllister, Chief Medical Officer. The presentations will give an overview of BioInvent's current and planned cancer immunotherapy programs, and the company's strategy to create shareholder value. The Company looks forward to engaging with all its stakeholders.

To attend the Capital Markets Day, please register by e-mail to [email protected] or by phone +46 46 286 85 54 no later than December 6. Following the event, a video recording will be published on BioInvent's website.

During the months of October and November, BioInvent's management will undertake an intensive program of investor meetings across the U.S., Europe, and Israel. As part of this program, BioInvent will host a Key Opinion Leader (KOL) event in New York on November 6. Details of this event, which will be webcast live and archived on BioInvent's website, will be announced shortly. At the KOL event, BioInvent's management and an invited scientific key opinion leader will engage with the U.S. investor community to present the Company's scientific and clinical value drivers.

About BioInvent 

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206 is currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.se.

For further information, please contact:
Martin Welschof, CEO
+46(0)46-286-85-50
[email protected]  

Hans Herklots, LifeSci Advisors
+41-79-598-71-49
[email protected]
 
BioInvent International AB (publ) 
Co. Reg. No. Org nr: 556537-7263 
Visiting address: Sölvegatan 41 
Mailing address: 223 70 LUND 
Phone: +46(0)46-286-85-50 
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE BioInvent

Related Links

http://www.bioinvent.com